Serum Hyaluronic Acid (HA) and Soluble Intercellular Adhesion Molecule-1 (sICAM-1) as Non-Invasive Markers of Liver Fibrosis in Viral Hepatitis, Schistosomiasis mansoni and Co-infected Patients

Khadiga Ahmed Ismail*, Sabah Abd-El-Ghany Ahmed and Noha Abdel Fattah Elleboudy
Parasitology Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

Abstract

**Background:** This study aimed to correlate serum Hyaluronic Acid (HA) and soluble intercellular adhesion molecule-1 (sICAM-1), with severity of liver fibrosis as clinically and histologically assessed in viral hepatitis, schistosomiasis mansoni and co-infected patients.

**Methods:** The study was performed on 4 groups: Group 1 (G1) 15 chronic hepatitis patients; Group 2 (G2) 15 chronic schistosomiasis mansoni co-infected with chronic hepatitis patients; Group 3 (G3) 15 chronic schistosomiasis mansoni without hepatitis patients; Group 4 (G4) 15 active schistosomiasis mansoni without hepatitis patients.

**Results:** The results showed a significant high level of HA and sICAM-1 in all groups compared to G4, while a significantly high level of HA in G2 compared to G3. There was a highly significant positive correlation between the level of HA and sICAM-1 and between both of them, and Child-Pugh clinical classification of patients with higher levels in Child-Pugh C. Also, serum level of both HA and sICAM-1 was positively correlated to the severity of liver fibrosis assessed by biopsy, with a highly significant higher level in advanced stages 4 and 5.

**Conclusions:** HA and sICAM-1 showed good diagnostic performance and could discriminate severe from mild liver fibrosis, enabling them to be used as valuable non-invasive markers to identify and follow up patients with liver fibrosis.

Keywords: Schistosomiasis mansoni; Hepatitis; Liver fibrosis; Non-invasive markers; Hyaluronic acid; Intercellular adhesion molecule-1

Introduction

Schistosomiasis mansoni is a chronic liver disease that is endemic in rural areas of Egypt. Some patients may acquire infection and develop minimal complications, while others may develop severe complications and progress to portal hypertension and cirrhosis, especially if co-infected with viral hepatitis [1,2]. Egypt has the highest worldwide prevalence for the concomitant infection of schistosomiasis and viral hepatitis, where the rates vary from 19.6%-64% for the hepatitis B (HBV), and 10.3%-67% for the hepatitis C virus (HCV) [3,4].

Liver fibrosis which results from chronic inflammation of hepatic parenchyma is a complex, dynamic process that involves an increase in extracellular matrix components, activation of cells producing matrix materials, cytokine release and tissue remodelling [5]. Liver biopsy is the gold-standard method for assessment of the liver fibrosis; however, it is an invasive procedure and is potentially dangerous [6].

Non-invasive markers have been developed to assess the severity of liver fibrosis. Among them, serum hyaluronic acid (HA) appears to be the most promising one [7]. HA is unbranched high-molecular-weight polysaccharide, and it represents a component of the extracellular matrix in virtually every tissue of the body. In the liver, HA is mostly synthesized by hepatic stellate cells and degraded by sinusoidal endothelial cells [8]. Some portion of tissue HA enters into the general circulation via lymphatics, and is mainly taken up by sinusoidal endothelial cells in the liver through hyaluronate receptors and degraded in lysosomes. Decreased function of sinusoidal endothelial cells in advanced liver diseases may raise serum levels of HA, through decreased number of hyaluronate receptors and reduced degradation of HA in the endothelial cells [9]. This marker is of interest in chronic liver diseases to avoid liver biopsy.

Granuloma formation is controlled and modulated by several cell types and protein interactions, primarily CD4+ T-cells, Th1 cytokines and cell adhesion factors [10,11]. Intercellular adhesion molecule-1 (ICAM-1) is present on endothelial cells, antigen presenting cells and fibroblasts, and belongs to the immunoglobulin superfamily of proteins [10,12]. ICAM-1 mediates granulocyte extravasation, lymphocyte-mediated cytoxicity and cell-cell interactions in immunologic responses [13]. Furthermore, the granulomatous response is mediated by eosinophils, the recruitment of which is critically dependent on ICAM-1 [14]. The soluble form of ICAM-1 (sICAM-1) may be shed from inflammatory cells, may be secreted by hepatocytes stimulated by inflammatory mediators, or may derive from passive liberation by necrotic hepatocytes [15]. The Th1 cytokines, IFN-γ and TNF-α, both trigger the release of sICAM-1 [16,17], and are known to play key roles in the modulation [18] and aggravation of hepatic fibrosis [19], respectively. The sICAM-1 is involved in lymphocyte and eosinophil recruitment and inflammatory, immune-mediated mechanisms [14,20]. Also, sICAM-1 plays a role in modulation of the schistosome granuloma [10]. Raised levels of sICAM-1 have been observed in the serum of patients with acute and chronic liver disorders [21]. Elevated expression has also been associated with intestinal schistosome infection and early granuloma formation in murine studies [22,23].

*Corresponding author: Khadiga Ahmed Ismail, Parasitology Department, Faculty of Medicine, An-Shams University, Cairo, Egypt; E-mail: khadigaahmed68@yahoo.com

Received October 08, 2012; Accepted October 22, 2012; Published October 25, 2012

Citation: Ismail KA, Ahmed SAEG, Elleboudy NAF (2012) Serum Hyaluronic Acid (HA) and Soluble Intercellular Adhesion Molecule-1(Sicam-1) as Non-Invasive Markers of Liver Fibrosis in Viral Hepatitis, Schistosomiasis mansoni and Co-infected Patients. J Bacteriol Parasitol 3:155. doi:10.4172/2155-9597.1000155

Copyright: © 2012 Ismail KA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Human studies have also noted a significant increase in sICAM-1 levels in serum and plasma of hepatic schistosomiasis patients [24-26].

The aim of the study was to correlate serum levels of two non-invasive markers of fibrosis HA and sICAM-1, with the severity of liver damage as clinically and histologically assessed in viral hepatitis, schistosomiasis mansoni and co-infected patients, to determine the importance of those markers as a screening procedure to identify patients with liver fibrosis in an endemic area for schistosomiasis mansoni and viral hepatitis.

Subjects and Methods

Patient’s selection

This study was carried out on 60 patients selected from Theodor Bilharz Research Institute in Giza, Egypt, during the period from January 2010 to January 2011. They were categorized (according to medical history and clinical evaluation) into 4 groups: Group 1 (G1) which included 15 chronic hepatitis patients (9 cases with HBV and 6 with HCV), as proved by past history of intestinal bilhariziasis or anti-bilharizial treatment, positive IHAT for schistosomiasis by indirect haemaglutination test (IHAT); Group 2 (G2) included 15 chronic schistosomiasis mansoni co-infected with chronic hepatitis patients, as proved by past history of intestinal bilhariziasis or anti-bilharizial treatment, positive IHAT for schistosomiasis and positive hepatitis marker (8 cases co-infected with HBV and 7 with HCV) for at least 6 months; Group 3 (G3) included 15 patients with chronic schistosomiasis mansoni without hepatitis, as proved by past history of intestinal bilhariziasis or anti-bilharizial treatment, positive IHAT for schistosomiasis and negative hepatitis marker; Group 4 (G4) included 15 patients with active schistosomiasis mansoni as viable Schistosoma mansoni ova were detected in their stool by direct, and or Kato-Katz technique [27] with positive IHAT for schistosomiasis and negative hepatitis marker. Patients with the following conditions were excluded from the study: other causes of liver disease, liver transplantation, prior interferon therapy or immunosuppressive therapy, insufficient liver tissue samples for staging of fibrosis and alcohol consumption (>30 g/day).

Patients of the studied groups were subjected to:

Serum processing: Blood samples (4-5 ml) were obtained from all the studied subjects. Sera were separated within 12 h of collection, using standard procedures and stored at -70°C until assay. Many laboratory parameters as: HBsAg (Axiom, Germany), anti-HCV (Murex, South Africa), Bilirubin, Albumin (Beckman Coulter chemistry systems), Prothrombin time (Siemens healthcare) and IHAT (Bilharzoise Fumouze Diagnostics/SERFIB, France) were measured, according to the manufacturer’s instructions.

Determination of serum sICAM-1 and HA: The serum fibrosis markers HA and sICAM-1 were measured using two different commercially available enzyme linked immunosorbent assay kits, specific for each one, in accordance with the manufacturer’s recommendations (HA-ELISA® and sICAM-1 ELISA®, R&D System, Inc, USA). Sample dilutions were 1/20, 1/10 for sICAM-1 and HA, respectively. Optical density (OD) was read at 450 nm. The serum levels were determined in one analytical batch in one working day.

Assessment of liver fibrosis severity: Liver fibrosis severity was assessed according to modified Child-Pugh classification, and liver biopsies results according to Ishak scoring system. Modified Child-Pugh classification is based on the degree of ascites, the plasma concentrations of bilirubin and albumin, the prothrombin time, and the grade of encephalopathy giving each point a score. A total score of 5-6 is considered grade A (well-compensated disease); 7-9 is grade B (significant functional compromise); and 10-15 is grade C (decompensated disease) [28].

Liver biopsy was carried out on 15 chronic hepatitis patients and 15 chronic schistosomiasis mansoni co-infected with chronic hepatitis patients (who were potential candidates for interferon), by the ultrasound-guided standard technique. Histological assessment of liver fibrosis was based on the Ishak scoring system [29], which is one of the commonly used scoring systems. The scoring is from 0 to 6, describing the architectural changes associated with different degrees of scar formation in the liver, which was done by a pathologist who was blinded to the results of serum indices in the study subjects.

Statistical analysis

Data management and analysis were made using SPSS version 15.0 for windows. Serum levels of HA and sICAM-1 are expressed in Mean ± SD and range. One-way ANOVA test, t-test and Pearson correlation coefficient test were used to analyse the results. The diagnostic performance of HA and sICAM-1 to discriminate patients with severe (stage 3-5) from mild (stage 1-2) liver fibrosis were evaluated, using receiver operating characteristics (ROC) curve with calculation of the area under the curves (AUC), best cut-off point, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). AUC of 1.0 is characteristic of an ideal test, whereas 0.5 indicates a test of no diagnostic value. The diagnostic accuracy was calculated by sensitivity, specificity, positive and negative predictive values, considering fibrosis as the disease. The nearer a curve shifted to the top left-hand corner of the graph, the more useful marker was it for the diagnosis. We determined the turning point of the curve to the best cut-off value for the diagnosis, and it was a maximal value at the sum of the sensitivity and specificity. P values <0.05 were considered statistically significant, and P values <0.001 were considered as statistically highly significant.

Ethical consideration

An informed consent was taken from all patients before taking the samples. The study was approved by Research Ethics Committee, Faculty of Medicine, Ain Shams University.

Results

Analysis of the results showed that the percent of Child-Pugh classification B was higher (40%) in the hepatitis group (G1), while that of classification C was higher (20%) in chronic schistosomiasis co-infected with hepatitis group (G2), as compared to the other groups. But, Child-Pugh classification A was higher in the active schistosomiasis group (G4) in comparison to other groups. Meanwhile, analysis of liver biopsy stages showed that the percent of advanced stages 2, 3, 4 and 5 were increased in the chronic schistosomiasis co-infected with hepatitis group, as compared to the hepatitis group (Table 1). According to the severity of liver disease of HA and sICAM-1, there was significant difference between the studied groups (p<0.05) by One-way ANOVA test, with significant higher level of sICAM-1 in the hepatitis, chronic schistosomiasis co-infected with hepatitis and chronic schistosomiasis without hepatitis groups, as compared to active schistosomiasis group. While, there was significantly higher level of HA in chronic schistosomiasis co-infected with hepatitis group, in comparison to chronic schistosomiasis without hepatitis group (Table 2). Furthermore, there was a highly significant (p<0.001) positive correlation between the level of HA and sICAM-1
in the studied groups (Figure 1), while there was a non-significant negative correlation between both levels of HA, sICAM-1 and egg count by kato-katz (mean egg count 190.7 and range 40-600 egg/gm stool) in the active schistosomiasis group.

The results showed highly significant difference between Child-Pugh classification groups as regarding the levels of HA and sICAM-1, with higher levels in C classification followed by B (ANOVA test, p<0.001) (Table 3). As regard of the liver biopsy fibrosis stages groups, there was a highly significant difference between them in the levels of HA, with high level in stage 5 followed by 4, and in the level of sICAM-1 with high level in stage 4 followed by 5 (ANOVA test, p<0.001) (Table 4). Also, a highly significant positive correlation between both levels of HA and sICAM-1 and Child-Pugh classification of patients was found (Figure 2 and 3), and a highly significant positive correlation between the level of HA and the stage of fibrosis, while a significant positive correlation between the level of sICAM-1 and the stage of fibrosis (Figure 4 and 5).

The AUC (CI 95%, 0.641-0.938) for HA was 0.824, with p<0.001, giving a good diagnostic performance, discriminating severe from mild liver fibrosis with a best cut off value of >350 ng/ml, sensitivity of 82.35, specificity of 84.6, PPV of 87.5 and NPV of 78.6. While for sICAM-1, AUC (CI 95%, 0.590-0.909) was 0.778, with p<0.05, giving a good diagnostic performance discriminating severe from mild liver fibrosis with a best cut off value of >54 ng/ml, sensitivity of 88.24, specificity of 82.35, PPV of 71.4 and NPV of 77.8. Pairwise comparison of ROCs of both markers (HA and sICAM-1) showed a non-significant difference (Figure 6).

Discussion

Fibrosis is the hallmark of chronic liver diseases, and it is one of the major causes of mortality and morbidity, related to both schistosomiasis and hepatitis [30]. The assessment of presence and severity of liver fibrosis is essential in determining treatment strategies, response to treatment, prognosis and potential risk for complications in patients with chronic liver disease [31].

Liver biopsy, the gold-standard method for diagnosing the severity of fibrosis, is an invasive tool and it is associated with rare but serious complications, such as bleeding, pneumothorax and perforation of the colon and gallbladder [32]. Therefore, because of these risks, cost and inconvenience, liver biopsy is certainly not the ideal procedure for repeated assessment of disease progression, especially during chronic hepatitis [33,34].

Use of non-invasive markers to predict fibrosis severity is important for monitoring transition to the severe forms of the disease, prognosis of these patients, and evaluation of fibrosis regression after treatment, especially in the areas where access to health care services is limited [35].

Many parameters for non invasive diagnosis of liver fibrosis were studied extensively in the past [36-38]. These parameters include routine laboratory tests, serum markers of fibrosis and inflammation used, either individually or in combination, ultrasonography and radiological imaging studies [33,34,39].

Ideally, a marker of hepatic fibrosis should be liver specific. It should also be able to measure the activity of the matrix deposition, reflect the underlying fibrosis, irrespective of the cause, should be easy to perform and yet sensitive enough to distinguish between the different stages of fibrosis [40].

HA has been described as a component of several fibrosis indexes, or as a single parameter for the non invasive assessment of fibrosis in hepatitis and schistosomiasis [41]. Combining HA level with other serum markers for assessing liver fibrosis has been considered in some

| Child-Pugh classifications | Stages of liver fibrosis |
|---------------------------|-------------------------|
| A                         | B                       |
| 1                         | 2                       |
| 3                         | 4                       |
| 5                         |                         |
| Hepatitis group (G1) n=15 | 7 (46.7%)               |
| 6 (40%)                   |
| 2 (13.3%)                 |
| 6 (40%)                   |
| 3 (20%)                   |
| 4 (26.7%)                 |
| 0 (0%)                    |
| 2 (13.3%)                 |

| Chronic schistosomiasis co-infected with hepatitis group (G2) n=15 | 7 (46.7%) |
|-------------------------------------------------------------------|-----------|
| 5 (33.3%)                                                         |
| 3 (20%)                                                           |
| 0 (0%)                                                            |
| 4 (26.7%)                                                         |
| 6 (40%)                                                           |
| 1 (6.7%)                                                         |
| 4 (26.7%)                                                         |

| Chronic schistosomiasis without hepatitis group (G3) n=15 | 10 (66.7%) |
|----------------------------------------------------------|-------------|
| 5 (33.3%)                                                |
| 0 (0%)                                                   |
| Not done                                                 |

| Active schistosomiasis group(G4) n=15 | 15 (100%) |
|--------------------------------------|-----------|
| 0%                                   |
| 0%                                   |
| Not done                             |

Table 1: Child-Pugh classifications and liver fibrosis stages by biopsy in the studied groups.

| n HA (ng/ml)* | sICAM-1 (ng/ml)* |
|--------------|------------------|
| Mean ± SD    | Range            | Mean ± SD    | Range            |
|-----------------|-----------------|
| 15 1006.7 ± 1584.7 | 30-4900 | 156 ± 113.1 | 15.8-365 |
| 15 880.7 ± 1070.7 | 60-3300 | 238.1 ± 197.5 | 17.8-605 |
| 15 286 ± 321.6 | 40-1100 | 165.3 ± 82.7 | 17.8-290 |
| 15 43.3 ± 32.4 | 10-100 | 80.8 ± 56.5 | 15.6-165 |

Table 2: Serum level of HA and sICAM-1 in the studied groups.

a=Significant difference between groups as regard level of HA and sICAM-1 (by Oneeway of ANOVA test, p<0.05)
b=Significant difference G1 as compared to G4
c=Significant difference G2 as compared to G3
d=Significant difference G2 as compared to G4
e=Significant difference G3 as compared to G4
b,c,d,e as compared by student-t test
other studies [42,43]. Most of the studies regarding serum markers of fibrosis have focused on hepatitis or schistosomiasis, as an isolated disease. The main objective of this study was to correlate levels of serum HA and sICAM-1, with the prediction of significant liver fibrosis as clinically and histologically assessed in hepatitis and schistosomiasis, not only as isolated diseases, but also as co-infections.

The results showed that there was significant difference between the studied groups regarding the serum level of HA and sICAM-1, with significant higher level of both markers in all groups compared to active schistosomiasis group with no intergroup discrimination between the etiological causes of fibrosis studied, except for the significantly higher level of HA in chronic schistosomiasis co-infected with hepatitis in comparison to chronic schistosomiasis without hepatitis group, and this observation is acceptable as patients of schistosomiasis co-infections with hepatitis exhibit higher necroinflammatory and hepatic fibrosis, with a significant hepatic fibrosis progression rate compared with hepatitis infection alone [31,44,45].

Both markers were positively correlated to the severity of liver fibrosis, and both succeeded in the discrimination between the liver fibrosis stages in the studied groups, as there was highly significant difference between the liver fibrosis stages regarding the levels of both markers. Patients with advanced stages of liver fibrosis had higher serum HA level, going in accordance with Sanvisens et al. [46], Saitou et al. [47] and Valva et al. [48]. This suggests that when liver damage develops, the liver more poorly metabolizes the HA, capillarization of the hepatic sinusoidal wall and the loss of the HA receptor of the sinusoidal endothelial cell occur, which is the main site of uptake and degradation of serum HA [49]. Also, endothelial function declines due to vascular obstruction by schistosoma eggs and chronic inflammation [50]. Patients in early stage of liver fibrosis possibly better metabolize HA in the liver than those with advanced liver fibrosis stages [51].

| Child-Pugh classifications | n   | HA (ng/ml)*  | sICAM-1 (ng/ml)* |
|---------------------------|-----|-------------|-----------------|
|                           |     | Mean ± SD   | Range           | Mean ± SD     | Range           |
| A                         | 39  | 123.8 ± 137 | 10-600          | 101 ± 79.5    | 15.6-200       |
| B                         | 16  | 645 ± 403.3 | 50-1700         | 207.4 ± 81.6  | 102.4-378      |
| C                         | 5   | 3820 ± 1098.6 | 2300-4900   | 470 ± 121.8   | 330-605        |

*a=*Highly significant difference between Child-Pugh classifications as regard level of HA and sICAM-1 with higher level in C classification followed by B (ANOVA test, p<0.001).

| Liver fibrosis stages | n   | HA (ng/ml)*  | sICAM-1 (ng/ml)* |
|-----------------------|-----|-------------|-----------------|
|                       |     | Mean ± SD   | Range           | Mean ± SD     | Range           |
| 1                     | 6   | 131.7 ± 111.8 | 30-350          | 92.2 ± 103.4  | 15.8-270        |
| 2                     | 7   | 328.6 ± 188.1 | 50-600          | 125.7 ± 103.3 | 17.8-290        |
| 3                     | 10  | 569 ± 492.7  | 60-1700         | 146.1 ± 79    | 19.6-265        |
| 4                     | 1   | 3300         | 3300            | 572           | 572             |
| 5                     | 6   | 2705 ± 1827.1 | 480-4900     | 407.7 ± 115.2 | 290-605        |

*a=*Highly significant difference between liver fibrosis stages as regard level of HA with higher level in stage 5 followed by 4 and as regard level of sICAM-1 with higher level in stage 4 followed by 5 (ANOVA test, p<0.001).

- Figure 1: Scatter-Plot showing a highly significant (p<0.001) positive correlation between serum level of HA and sICAM-1 in the studied groups.
- Table 3: Relation between each one of the Child-Pugh classifications and level of HA and sICAM-1 in the studied groups.
- Table 4: Relation between each one of liver fibrosis stages and level of HA and sICAM-1 in the studied groups.
- Figure 2: Scatter-Plot showing a highly significant (P<0.001) positive correlation between HA and the Child-Pugh classification.
- Figure 3: Scatter-Plot showing a highly significant (P<0.001) positive correlation between sICAM-1 and the Child-Pugh classification.
- Figure 4: Scatter-Plot showing significant positive correlation (P<0.05) between HA concentration and the stage of fibrosis.
We also observed the same pattern for sICAM-1 in the patient groups agreeing with Estere et al. [25]. Most likely, elevated sICAM-1 levels are a result of the inflammatory responses leading to granuloma formation as inflammation and cytolsis lead to an up-regulation in the expression of tissue ICAM-1 derived from hepatocytes and vascular endothelium [52], with higher sICAM-1 levels in severe disease forms reflecting the more intense inflammation which may be occurring in these patients [24], and it could reflect the activation of undergoing immunological mechanisms [53]. This suggests that sICAM-1 may participate in the pathology associated with schistosomiasis infection and it could be employed as a potential morbidity marker in schistosomiasis mansoni infection.

Also, there was a highly significant positive correlation between the levels of HA and sICAM-1 in the studied groups. This relationship between HA and sICAM-1 levels was not unexpected, since both parameters were independently correlated with the disease severity [25].

Furthermore, both markers were highly significant and positively correlated to Child-Pugh classification of patients, and both succeeded in discrimination between Child–Pugh classification groups with higher levels in C classification followed by B. These results are supported by Thomson et al. [54], 4 who found that sICAM-1 levels were positively correlated to summary assessment of primary biliary cirrhosis severity by Child-Pugh classification. These suggest that both markers can be accurate indicators to assess the patient’s clinical condition and prognosis. Körner et al. [55] concluded that a modification of the Child-Pugh classification of liver cirrhosis by inclusion of HA as a new marker, had significantly improved the predictive power of the classification. Our results suggest that the inclusion of both markers together can reinforce this predictive power.

When diagnostic accuracy of HA and sICAM-1 in discriminating severe from mild liver fibrosis in this study were assessed by ROC curve, AUC (CI 95%) for HA was 0.824, while for sICAM-1 was 0.778, with a non significant pairwise comparison between ROC curves of both markers, and these indicate a good diagnostic performance and introduce the availability of combining both markers. These observations are in agreement with Resino et al. [41] and Valva et al. [48]. Many fibrosis experts would consider non-invasive tests for fibrosis with an AUC of 0.85-0.90, to be as good as liver biopsies for staging fibrosis [36]. Some authors have argued that some non-invasive markers of fibrosis might be even more accurate than biopsies, and that most of the significantly discordant results between biopsies and non-invasive tests may be due to the method of obtaining biopsies that does not demonstrate the actual liver fibrosis state (sampling error when performing the biopsies) [56].

Furthermore, the results showed a non-significant negative correlation between both levels of HA, sICAM-1 and egg count by kato-katz in the active schistosomiasis group, and this is supported by Mwatha et al. [26] as their levels increase with fibrosis progression [57]. It is not surprising that no correlation between these morbidity markers and egg counting could be found, as egg counting represents a poor measure of parasite-associated morbidity [58].

It was concluded that measurement of serum HA and sICAM-1 levels can discriminate between patients with different degrees of liver fibrosis, as assessed by both histological and clinical diagnoses. Therefore, the results suggest the inclusion of both HA and sICAM-1 serum levels determination in clinical practice, prognosis and management of hepatitis, schistosomiasis and co-infected patients, and this may be helpful for the early diagnosis of fibrosis degree when liver biopsy is contraindicated, or when access to health care services is limited.

Acknowledgement

The authors are grateful to all the staff members at Tropical medicine and Pathology departments, Theodor Bilharz Research Institute in Giza for their kind help in clinical evaluation of the patients, collection of samples and histological assessment of liver fibrosis by biopsy.

References

1. Basily S, Dunn MA, Farid Z, Kilpatrick ME, El-Masry NA, et al. (1983) Chronic hepatitis B in patients with schistosomiasis mansoni. J Trop Med Hyg 86: 67-71.
2. Mohamed MK, Bakr I, El-Huseiny M, Arafa N, Hassan A, et al. (2006) HCV-related morbidity in a rural community of Egypt. J Med Virol 78: 1185-1189.
3. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, et al. (1997) Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 28: 236-243.
4. el-Sayed HF, Abaza SM, Mehanna S, Winch PJ (1997) The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop 68: 229-237.
5. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, et al. (1998) Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 5: 187-192.
6. Schiff ER, Schiff L (1993) Needle biopsy of the liver. Diseases of the Liver. (7thedn), Lippincott Co, Philadelphia.

7. Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, et al. (2005) serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBsAg-negative chronic hepatitis B. BMC Gastroenterol 5: 32.

8. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, et al. (2005) Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25: 779-786.

9. Tamaki S, Ueno T, Torimura T, Sata M, Tanikawa K (1996) Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in rats with liver cirrhosis. Gastroenterology 111: 1049-1057.

10. Jacobs W, Van Marck E (1998) Adhesion and co-stimulatory molecules in the pathogenesis of hepatic and intestinal Schistosoma mansoni. Mem Inst Oswaldo Cruz 93: 523-529.

11. Stadecker MJ, Asahi H, Finger E, Hernandez HJ, Rutitzky LI, et al. (2004) The Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, et al. (2005) Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in rats with liver cirrhosis. Gastroenterology 111: 1049-1057.

12. Rothlein R, Mainolfi EA, Czajkowski M, Martin SD (1991) A form of circulating ICAM-1 in human serum. J Immunol 147: 3788-3793.

13. Forbes E, Hulett M, Ahrens R, Wagner N, Smart V, et al. (2006) ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol 80: 330-341.

14. Lim AG, Jazrawi RP, Ahmed HA, Levy JH, Zuin M, et al. (1994) Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis. Hepatology 20: 892-898.

15. Paolioli F, Battifora M, Riccio AM, Pesce G, Canonica GW, et al. (1997) Intercellular adhesion molecule-1 on cultured human epithelial cell lines: influence of proinflammatory cytokines. Allergy 52: 521-531.

16. Leung KH (1999) Release of soluble ICAM-1 from human lung fibroblasts, aortic smooth muscle cells, dermal microvascular endothelial cells, bronchial epithelial cells, and keratinocytes. Biochem Biophys Res Commun 260: 734-739.

17. Bonnard P, Remoué F, Schacht AM, Pialoux G, Riveau G (2006) Association between serum cytokine profiles and schistosomiasis-related hepatic fibrosis: infection with Schistosoma japonicum versus S. mansoni. J Infect Dis 193: 746-749.

18. Booth M, Mwatha JK, Joseph S, Jones FM, Kadzo H, et al. (2004) Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 172: 1295-1303.

19. Radi ZA, Kehri ME Jr, Ackermann MR (2001) Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J Vet Intern Med 15: 516-529.

20. Abdalla A, Sheesha AA, Shokeir M, el-Agrody O, el-Regal ME, et al. (2002) Serum intercellular adhesion molecule-I in children with chronic liver disease: relation to disease stage, immune activity and cholestasis. Hepatology 20: 882-888.

21. Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, et al. (2004) Kinetics of haematopoietic progenitor cell mobilisation during schistosomiasis mansoni coinfection: relation to progression of liver fibrosis. Inst Oswaldo Cruz 105: 460-466.

22. Thuluvath PJ, Krok KL (2006) Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 101: 1497-1499.

23. Castera L, Forms X,Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.

24. Fontana R, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadh D, et al. (2008) Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 47: 789-798.

25. Köpke-Aguiar LA, Martins JR, Passerotti CC, Toledo CF, Nader HB, et al. (2002) Serum hyaluronic acid as a comprehensive marker to assess severity of liver disease in schistosomiasis. Acta Trop 84: 117-126.

26. Mwatha JK, Kimani G, Kamau T, Mbugua GG, Ouma JH, et al. (1998) High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. J Immunol 160: 1992-1999.

27. Katz N, Chaves A, Pellegrino J (1972) A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 14: 397-400.

28. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 846-849.

29. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.

30. Abath FG, Morais CN, Montenegro CE, Wynn TA, Montenegro SM, et al. (2006) Immunopathogenic mechanisms in schistosomiasis: what can be learnt from human studies? Trends Parasitol 22: 85-91.

31. Morais CN, Carvalho Bde M, Melo WG, Melo FL, Lopes EP, et al. (2010) Correlation of biological serum markers with the degree of hepatic fibrosis and necroinflammatory activity in hepatitis C and schistosomiasis patients. Mem Inst Oswaldo Cruz 105: 460-466.

32. Althal NH (2003) Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests? Hepatology 37: 972-974.

33. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, et al. (2003) Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 38: 224-230.

34. Hui AV, Chan HL, Wong VW, Liew CT, Chiu AM, et al. (2005) Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 100: 616-623.

35. Gressner OA, Weiskirchen R, Gressner AM (2007) Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 11: 1031-1051.

36. Shiga G (2008) Serum hyaluronic acid: a promising marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol 14: 161-162.

37. Resino S, Bellón JM, Asensio C, Micheloud D, Miralles P, et al. (2010) Can serum hyaluronic acid replace simple non-invasive indices to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis 10: 244.

38. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, et al. (2004) Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in HIV/HCV infected individuals. J Hepatol 41: 935-942.

39. Rosenberg WM, Voelker M, Thiel R, Becka M, Torti B, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713.

40. Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, et al. (2004) Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: correlation to progression of liver fibrosis. J Infect Dis 189: 1140-1150.

41. Kamal SM, Turner B, He Q, Rasanack J, Bianchi L, et al. (2006) Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43: 771-779.

42. Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, et al. (2009) Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic
hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 16: 513-518.

47. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, et al. (2005) Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 28: 476-481.

48. Valva P, Cacciato P, Diaz Carrasco JM, Gidano A, Galdame O, et al. (2011) The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One 6: e23218.

49. Tanikawa K (1998) Serum hyaluronic acid in clinical practice. intern med 37: 565.

50. Marinho CC, Bretas T, Voieita I, Queiroz LC, Ruiz-Guevara R, et al. (2010) Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for Schistosomiasis mansoni: a field-based study in Brazil. Mem Inst Oswaldo Cruz 105: 471-478.

51. Parsian H, Rahimpour A, Nouri M, Somi MH, Qujeq D, et al. (2010) Serum hyaluronic acid and laminin as biomarkers in liver fibrosis. J Gastrointestin Liver Dis 19: 169-174.

52. Capra F, De Maria E, Lunardi C, Marchiori L, Mezzelani P, et al. (2000) Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis c virus: a prognostic marker for responses to interferon treatment. J Inf Dis 181: 425-431.

53. Bruno CM, Sciacca C, Cillo D, Bertino G, Marchese AE, et al. (2005) Circulating adhesion molecules in patients with virus-related chronic diseases of the liver. World J Gastroenterol 11: 4566-4569.

54. Thomson AW, Satoh S, Nussler AK, Tamura K, Woo J, et al. (1994) Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin Exp Immunol 95: 83-90.

55. Kömer T, Kropf J, Kosche B, Kristahl H, Jaspersen D, et al. (2003) Improvement of prognostic power of the Child-Pugh classification of liver cirrhosis by hyaluronan. J Hepatol 39: 947-953.

56. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, et al. (2004) Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50: 1344-1355.

57. Ellis MK, Li Y, Hou X, Chen H, McManus DP (2008) sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in Schistosomiasis japonica. Int J Parasitol 38: 717-723.

58. Wiest PM (1996) The epidemiology of morbidity in schistosomiasis. Parasitol Today 12: 215-220.